Evidence map›Paper›PMID 30873737›Full record

Observational studyAsia-Pacific journal of clinical oncology2019

A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.

Dalin He, Zhongquan Sun, Jianming Guo, Zhigen Zhang, Yuxi Shan, Lulin Ma, Hanzhong Li, Jie Jin, Yiran Huang, Jiaquan Xiao and 2 more

Open access · bronzeAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Asia-Pacific journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 1 country.

Dalin HeThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhongquan SunHuadong Hospital Affiliated to Fudan University, Shanghai, China.
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhigen ZhangSir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China.
Yuxi ShanThe Second Affiliated Hospital of Soochow University, Suzhou, China.
Lulin MaThe Third Hospital of Peking University, Beijing, China.
Hanzhong LiPeking Union Medical College Hospital, Beijing, China.
Jie JinPeking University First Hospital, Beijing, China.
Yiran HuangRenji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jiaquan XiaoThe Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou.
Qiang WeiWest China Hospital, Sichuan University, Chengdu, China.
Dingwei YeFudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0000-0003-4974-3780
Peking University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNFudan University · CNFudan University Shanghai Cancer Center · CNRenji Hospital · CNSecond Affiliated Hospital of Zhejiang University · CNSichuan University · CNSir Run Run Shaw Hospital · CNSoochow University · CNSun Yat-sen University · CN

Funding

Sanofi China
6 · The paper itself

Abstract

aimTo investigate the use of docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice in China.

methodsThis single-arm, prospective, observational study was conducted at 32 study centers in China and included male patients aged ≥18 years with histologically confirmed prostate cancer who received ≥1 dose of docetaxel following failure of hormonal therapy (disease progression with serum testosterone <50 ng/dL). The primary aim was to investigate patterns of docetaxel treatment.

resultsOverall 403 patients were included between August 2011 and June 2016; patients initiated docetaxel after failure of first- (42.2% [170]), second- (31.0% [125]) and ≥third-line (12.7% [51]) hormonal therapy, estramustine (11.4% [46]) or other (2.7% [11]). The planned cycles of docetaxel therapy were completed by 30.8% of patients, and the mean (SD) number of cycles received was 4.4 (2.86). Median overall survival (mOS) was 22.4 (95% CI, 20.4-25.8) months and the prostate-specific antigen (PSA) response rate in patients with available data was 70.9% (168/237), with no differences in mOS and PSA response rates between treatment settings. Subgroup analysis revealed higher mOS in patients without visceral metastasis versus those with such metastases (22.9 vs. 17.4 months; P = 0.022). No new safety signals were observed and the most common adverse events associated with docetaxel were granulocytopenia (5%) and leukopenia (4.5%).

conclusionData from this study showed that around three-quarters of Chinese patients with mCRPC treated with docetaxel initiated treatment following first- or second-line hormonal therapy and no new safety signals were observed.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsChinaDisease ProgressionDocetaxelHumansMaleMiddle AgedProspective StudiesProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantAntineoplastic AgentsDocetaxelProstate-Specific Antigencastration-resistant prostate cancerdocetaxelobservational

Identifiers

PMID30873737
PMCPMC6850484
OpenAlexW2921260961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.